A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications CNS cancer; Lymphoma; Testicular cancer
- Focus Therapeutic Use
- Acronyms CheckMate 647
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 26 Jan 2018 Planned primary completion date changed from 12 Aug 2018 to 9 Jun 2019.
- 09 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 21 Apr 2017 Status changed from recruiting to active, no longer recruiting.